Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients

Frontiers in Oncology

Oncology

Gerald W. Prager¹  Theresa Schmalfuss²  Hossein Taghizadeh³  Josef Singer⁴  Agnieszka Maj-Hes⁵ 

[1] Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria;Medical University Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria;Division of Oncology, Department of Internal Medicine I, University Hospital St. Pölten, St. Pölten, Austria;Karl Landsteiner University of Health Sciences, Krems, Austria;Center for Cancer Research, Medical University of Vienna, Vienna, Austria;Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria;Division of Oncology, Department of Internal Medicine I, University Hospital St. Pölten, St. Pölten, Austria;Karl Landsteiner University of Health Sciences, Krems, Austria;Karl Landsteiner Institute for Oncology and Nephrology, St. Pölten, Austria;Center for Cancer Research, Medical University of Vienna, Vienna, Austria;Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria;Karl Landsteiner University of Health Sciences, Krems, Austria;Division of Oncology, Department of Internal Medicine II, University Hospital Krems, Krems, Austria;Medical University Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria;Department of Pulmonology, Klinik Penzing, Vienna, Austria;

关键词: biliary tract cancer;    molecular aberrations;    molecular profiling;    precision medicine;    precision oncology;   

DOI  :  10.3389/fonc.2023.1143825

 received in 2023-01-13, accepted in 2023-04-25,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionMetastatic biliary tract cancer (BTC) is a rare and aggressive entity associated with poor prognosis. It represents a major challenge for adequate treatment strategies. In recent years, BTC has become a model for precision medicine in gastrointestinal oncology. Therefore, the analysis of the individual molecular profile in BTC patients may lead to targeted therapies for the benefit of patients.MethodsIn this Austrian, tricentric, real-world, retrospective analysis, we investigated patients diagnosed with metastatic BTC who underwent molecular profiling between 2013 and 2022.ResultsIn total, 92 patients were identified in this tricentric analysis and 205 molecular aberrations, including 198 mutations affecting 89 different genes in 61 patients were found. The predominant mutations were in KRAS (n=17; 22.4%), TP53 (n=17; 22.4%), PIK3CA (n=7; 9.2%), FGFR2 (n=7; 9.2%), DNMT3A (n=7; 9.2%), IDH1 (n=7; 9.2%), IDH2 (n=6; 7.9%), CDKN2A (n=6; 7.9%), BAP1 (n=4; 5.3%), NF1 (n=4; 5.3%), and NF2 (n=4; 5.3%). Three patients had HER2 amplification. MSI-H status and FGFR2 fusion genes were each observed in two different patients. One patient had a BRAF V600E mutation. Eventually, 10 patients received targeted therapy, of whom one-half derived clinical benefit.ConclusionsMolecular profiling of BTC patients is implementable in routine clinical practice and should be regularly employed to detect and exploit molecular vulnerabilities.

【 授权许可】

Unknown   
Copyright © 2023 Taghizadeh, Schmalfuss, Maj-Hes, Singer and Prager